South Korea-based contract development and manufacturing organisation Samsung Biologics (KRX:207940) announced on Wednesday that it has invested in US generative biology company Generate:Biomedicines.

Founded by Flagship Pioneering, Generate applies AI-based optimisation and de novo generation to discover and design novel protein therapeutics. It has a pipeline of approximately 20 programmes from preclinical to clinical development across oncology, immunology and infectious diseases.

This investment is part of Samsung Biologics' efforts to drive growth and innovation in the biopharmaceutical sector. It was made through the Samsung Life Science Fund, which was established jointly between Samsung Biologics, Samsung C&T and Samsung Bioepis, and managed by Samsung Venture Investment Corporation.

John Rim, Samsung Biologics' president and CEO, said: "We see great potential in Generate to develop first- and best-in-class therapeutics. Leveraging Generate's strengths in AI and machine learning, we look forward to creating an ecosystem for development, manufacturing and R&D collaboration to advance next-generation medicines in areas with unmet needs."

Mike Nally, CEO of Generate:Biomedicines, added: "Funding from leading partners like Samsung enables us to continue advancing our platform, generating high-quality data, and empowering our exceptional team to tackle some of the toughest challenges in human health. With clinical programmes already in progress and plans to add three to six more within the next 18 months, we are turning technological promise into tangible outcomes."